Gossamer Bio (NASDAQ:GOSS) Announces Quarterly Earnings Results

Gossamer Bio (NASDAQ:GOSS) announced its quarterly earnings results on Tuesday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.03), MarketWatch Earnings reports.

Shares of NASDAQ:GOSS opened at $9.92 on Wednesday. The firm’s 50 day moving average price is $12.84 and its 200-day moving average price is $17.33. Gossamer Bio has a twelve month low of $7.52 and a twelve month high of $27.15. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $619.44 million and a PE ratio of -0.44.

In related news, insider Jakob Dupont sold 1,994 shares of the firm’s stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $15.81, for a total value of $31,525.14. Following the transaction, the insider now owns 1,994 shares of the company’s stock, valued at $31,525.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 23.30% of the stock is owned by corporate insiders.

GOSS has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective (down from $34.00) on shares of Gossamer Bio in a report on Tuesday, December 17th. Bank of America began coverage on shares of Gossamer Bio in a report on Tuesday, December 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Barclays assumed coverage on shares of Gossamer Bio in a research report on Thursday, February 27th. They issued an “overweight” rating and a $21.00 target price for the company. Zacks Investment Research upgraded shares of Gossamer Bio from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Wednesday, February 5th. Finally, ValuEngine raised Gossamer Bio from a “hold” rating to a “buy” rating in a report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $25.83.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Further Reading: What is cost of equity?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.